908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

908 Devices reports revenue growth, eyes biopharma sector improvement

908 Devices showed solid financial performance in 2022, with revenue growth and strategic expansions.
While facing challenges like macro headwinds and lower REBEL placements, the company is focused on innovation.
Opportunities lie in biopharma sector improvement, product utilization rates, and unit growth expectations.
Maintaining a strong cash position and disciplined capital deployment are key strengths for future growth.

908 Devices reports revenue growth and strategic partnerships driving innovation

908 Devices delivered solid performance in Q1 2023, marked by revenue growth, strong recurring revenue, and strategic partnerships driving innovation and market expansion.
While facing challenges in operating expenses and gross margins, the company's focus on handheld devices, recurring revenues, and cost management positions it for future success.
With a robust cash position, ongoing product launches, and a diverse sales funnel, 908 Devices is poised to capitalize on opportunities in the biopharma and cell therapy markets.

908 Devices reports revenue growth and strategic focus for growth

908 Devices showcased revenue growth and strong performance in key product segments. While managing expenses prudently and focusing on key markets, the company faces challenges with a net loss and the need for additional handheld unit growth. Opportunities lie in upcoming product launches, government contracts, and pipeline updates.

908 Devices reports Q3 revenue growth, eyes strong 2024 prospects

908 Devices showed solid performance in Q3 2023, driven by growth in handheld devices and strategic collaborations. Despite challenges in the bio-processing space, the company remains optimistic about future growth and product development.
With a strong cash position, no debt, and a focus on returning to high growth rates, 908 Devices is poised for success in 2024. The company's emphasis on process analytical technology tools and expanding market offerings presents promising opportunities for the future.
While facing challenges in revenue expectations and utilization rates, 908 Devices is actively addressing these issues to drive sustainable growth. The company's commitment to innovation and market expansion positions them well for long-term success.

908 Devices reports strong Q4 performance and optimistic outlook for 2024

908 Devices showed revenue growth and improved net loss in Q4 2023, with a positive outlook for 2024.
The company's strong cash position, successful partnerships, and product confidence are key strengths.
Challenges include margin pressures from pricing adjustments and increased spending.
Opportunities lie in revenue growth guidance, customer interest in new products, and market expansion plans.

908 Devices reports solid Q1 performance, eyes growth opportunities

908 Devices had a strong start in Q1 2024, driven by revenue growth and RedWave acquisition.
Challenges include net loss, declining desktop product revenue, and cost management.
Opportunities lie in engagement with cell therapy accounts, revenue synergies, and cash flow improvement.
Strategic fit of RedWave acquisition offers growth potential and cost synergies in the long term.

908 Devices reports solid Q2 earnings, eyes growth through diversification

908 Devices demonstrated strong revenue growth in Q2 2024, driven by robust performance in handheld forensics devices.
While facing challenges in desktop product revenue, the company's focus on recurring revenue and market expansion bodes well for future prospects.
Strategic adjustments and continued emphasis on operational excellence position 908 Devices for sustained success in diverse markets.

908 Devices faces revenue challenges but pursues growth opportunities

908 Devices reported mixed financial performance in Q3 2024, with revenue growth but falling short of expectations, leading to a net loss.
The company is taking steps to optimize operations, identify growth drivers, and drive margin expansion for future success.
Challenges include revenue guidance adjustments, competitive pressures, and financial losses, which require strategic responses.
Opportunities lie in product innovation, strategic partnerships, and effective implementation of sales strategies to drive growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)-- #automation--Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge's bioreactors with 908 Devices' MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of bioprocessing, the continuous monitoring of glucose and lactate levels is cr.

Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

908 Devices Inc. (NASDAQ:MASS ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Kelly Gura - Gilmartin Group Kevin Knopp - Chief Executive Officer and Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Sam Martin - William Blair Hannah Hefley - Stepehens Chad Wiatrowski - TD Cowen Operator Hello, and welcome to the 908 Devices' Third Quarter 2024 Financial Results Conference Call. My name is Elliot, and I'll be coordinating your call today.

908 Devices Inc. (MASS) Q3 2024 Earnings Call Transcript

908 Devices Inc. (MASS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.22 per share a year ago.

908 Devices Inc. (MASS) Reports Q3 Loss, Lags Revenue Estimates

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024. “While we are pleased that our revenue increased year-over-year due to our newly acquired products, our third quarter results fell short of our expectations due to challenges from the delayed FY24 federal budget, delays with advancing international contracts, and ongoing softness in the.

908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences. Stifel Healthcare Conference, New York, NY Fireside chat on Tuesday, November 19 at 8:35 a.m. Eastern Time 26th Annual Stephens Investment Conference, Nashville, TN Fireside chat on Wednesday, November 20 at 3 p.m. Central Time / 4 p.m. Eastern Time Interested parties may access a live.

908 Devices to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The we.

908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming virtual Craig-Hallum Bioprocessing Conference. 908 Devices' management is scheduled to host a fireside chat on Thursday, September 19 at 10:15 a.m. Eastern Time. Interested parties may access a replay webcast link following the conference on the “Investors” section of the company website at 908devices.com. Ab.

908 Devices to Participate in Craig-Hallum Bioprocessing Conference

908 Devices Inc. (MASS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago.

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024. "We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently,” said Kevin J. K.

908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

Bicycle Therapeutics Plc - ADR

Bentley Systems

Mueller Industries

New Jersey Resources

Orthofix International

D-Wave Quantum Inc

Summit Therapeutics

Zoetis

SALT LAKE CITY--(BUSINESS WIRE)--As regulatory deadlines approach, 25 snack food suppliers align with ReposiTrak for its state-of-the-art, hardware-free traceability solutions.

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: 908 Devices Inc. (MASS) Q2 Earnings Expected to Decline

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming Canaccord Genuity 44th Annual Growth Conference. 908 Devices' management is scheduled to present on Tuesday, August 13 at 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: 908devices.com. About 908 Device.

908 Devices to Participate in Canaccord Genuity 44th Annual Growth Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webc.

908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of.

908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

BOSTON--(BUSINESS WIRE)-- #hazmat--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of 908 Devices' acquisition of RedWave Technology, can now quantify nearly 5,000 airborne chemicals. XplorIR empowers fire departments, HAZMAT teams and other first responders with mission-critical information and enab.

908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors

Akoya Biosciences Inc

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

Olink Holding AB

Singular Genomics Systems

QIAGEN

Quantum-Si

Revvity Inc

Seer

Thermo Fisher Scientific

10X Genomics

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

The average of price targets set by Wall Street analysts indicates a potential upside of 133.7% in 908 Devices (MASS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know

908 Devices (MASS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

908 Devices Inc. (NASDAQ:MASS ) Q1 2024 Results Conference Call April 30, 2024 8:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Co-Founder and Chief Executive Officer Joe Griffith - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Jacob Johnson - Stephens Steven Mah - TD Cowen Dan Arias - Stifel Puneet Souda - Leerink Partners Operator Hello, everyone, and welcome to the 908 Devices First Quarter 2024 Financial Results Conference Call. My name is Seb and I'll be the operator for your call today.

908 Devices Inc. (MASS) Q1 2024 Earnings Call Transcript

908 Devices Inc. (MASS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.39 per share a year ago.

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024. "We had a solid start to the year with topline revenue of $10 million for the first quarter and continued to see robust demand for our handheld devices as applications for chemical detection and identification at the point of need gain further traction in the US and internat.

908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical identification of bulk materials. FTIR (Fourier Transform Infrared), an optical spectroscopy technology, is highly regarded for its specific substance identification abili.

908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908device.

908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024

Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are leading companies in the life science tools industry. Despite a long history of success with those firms, I believe long-term investors should diversify into growth opportunities that underlie the industry. 908 Devices, Inc. is a promising company focused on first-in-class mass spectrometry and bioprocess analysis tools, with a profitable future in store.

908 Devices: Rare Early-Stage Bioprocess Investment Opportunity

Bitdeer Technologies Group

NVIDIA

Robinhood revolutionized commission free investing, and it continues to do so today.

News for 908 Devices Stock (MASS)